CR-CP Life Science Fund, formed by conglomerates China Resources Group and Charoen Pokphand Group, co-led a $25m series C round for Israel-based ophthalmic implant developer EyeYon Medical yesterday.
The round was co-led by an unnamed strategic leader in the ophthalmic industry and it also featured GHS Fund, BPC, Triventures, Rimonci Capital, Pontifax and Diamond BioFund.
EyeYon’s products include EndoArt, a synthetic implant designed to treat chronic corneal oedema, and Hyper CL, a contact lens treatment for a variety of corneal conditions that works as an alternative to eye drops.
The company had secured a total of $4.3m as of 2015, when it received $3.6m from investors including Pontifax, TriVentures, Israel’s Office of the Chief Scientist and Docor International, a subsidiary of foundation Van Leer Group described as an existing investor.
The 2015 round was followed by $6.5m from ophthalmology product and services provider Gauss Medical, Pontifax, Triventures, Rimonci Capital and grant funding from Office of the Chief Scientist two years later.
